Cargando…
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
BACKGROUND: Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a lower risk of cardiovascular (CV) events is not yet established. METHODS AND RESULTS: Patient-level, pooled analysis...
Autores principales: | Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark J, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Lawrence, David, Friedman, Andrew, Garcia Conde, Lorena, Wright, R Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825807/ https://www.ncbi.nlm.nih.gov/pubmed/36331326 http://dx.doi.org/10.1093/eurheartj/ehac594 |
Ejemplares similares
-
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022) -
Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023) -
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
por: Raal, Frederick, et al.
Publicado: (2023) -
Cis-Regulatory Changes Associated with a Recent Mating System Shift and Floral Adaptation in Capsella
por: Steige, Kim A., et al.
Publicado: (2015) -
Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome:
the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022)